MUC5AC
Mucin-5AC
As of the edition of 20 October 2026, MUC5AC (mucin-5AC, UniProt P98088) has 4 drugs tested at it and 3 companies on the list, 2 on route A and 0 on route B.
Sources: UniProt, ClinicalTrials.gov, ChEMBL, FDA Orange Book and Purple Book, Pharos.
The protein
- UniProt
- P98088
- How well studied
- Biology documented; no tool compounds or approved drug yet
- Where it sits in the cell
- Secreted
- Solved structures
- 14
- Disease areas
- Cancer; Digestive system; Hormones
- Registered trials of its drugs
- 6
Drugs at this target
| Status | Count |
|---|---|
| Went quiet | 1 |
| Stopped | 2 |
| Status not established | 1 |
| Total | 4 |
| Drug | Status | Furthest phase | US protection |
|---|---|---|---|
| Ensituximab | Stopped | Phase 2 | none listed |
| Yttrium y 90 clivatuzumab tetraxetan | Stopped | Phase 2 | none listed |
| Clivatuzumab tetraxetan | Went quiet | Phase 2 | none listed |
| NMK89 | Status not established | Phase 1 | none listed |
4 of 4 drugs, the most tested first.
Companies at this target
| Where the company stands | Companies |
|---|---|
| Route A | 2 |
| Undetermined | 1 |
| Total on the list | 3 |
| Company | Route |
|---|---|
| Gilead Sciences | Route A |
| Precision Biologics | Route A |
The other 1 company at MUC5AC
In the product3 companies in all; 1 is not named here, and no score is.
See the 3 companies at MUC5AC, ranked, with the facts behind eachRequest access. Nothing is shown until you do.